DSS colitis promotes tumorigenesis and fibrogenesis in a choline-deficient high-fat diet-induced NASH mouse model

Biochemical and Biophysical Research Communications

Volumn 470, Issue 1, 2016, Pages 15-21

  Achiwa, Koichi ^a   Ishigami, Masatoshi ^a   Ishizu, Yoji ^a   Kuzuya, Teiji ^a   Honda, Takashi ^a   Hayashi, Kazuhiko ^a   Hirooka, Yoshiki ^a   Katano, Yoshiaki ^b   Goto, Hidemi ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b FUJITA HEALTH UNIVERSITY BANTANE HOSPITAL   (Japan)

Author keywords

Choline deficient high fat; Colitis; Fibrosis; Nonalcoholic steatohepatitis; Tumorigenesis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA SMOOTH MUSCLE ACTIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHOLESTEROL; CHOLINE; DEXTRAN SULFATE; DRINKING WATER; GLUCOSE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; DISEASE SEVERITY; FECES MICROFLORA; FIBROGENESIS; GENE EXPRESSION; INFLAMMATORY CELL; INTESTINE MUCOSA PERMEABILITY; LIPID DIET; LIPID STORAGE; LIVER CARCINOGENESIS; LIVER HISTOLOGY; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; VITAMIN DEFICIENCY; WEIGHT CHANGE; ANIMAL; C57BL MOUSE; CARCINOGENESIS; CHEMICALLY INDUCED; DRUG EFFECTS; INTESTINE ABSORPTION; INTESTINE FLORA; LIVER CIRRHOSIS; PATHOLOGY;

ANIMALS; CARCINOGENESIS; CHOLINE DEFICIENCY; COLITIS; DEXTRAN SULFATE; DIET, HIGH-FAT; GASTROINTESTINAL MICROBIOME; INTESTINAL ABSORPTION; LIVER CIRRHOSIS; MALE; MICE; MICE, INBRED C57BL; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84955691102     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2015.12.012     Document Type: Article

References (32)

1. N. Chalasani, Z. Younossi, J.E. Lavine, A.M. Diehl, E.M. Brunt, K. Cusi, M. Charlton, and A.J. Sanyal The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology Gastroenterology 142 2012 1592 1609
2. L.A. Adams, J.F. Lymp, J. St Sauver, S.O. Sanderson, K.D. Lindor, A. Feldstein, and P. Angulo The natural history of nonalcoholic fatty liver disease: a population-based cohort study Gastroenterology 129 2005 113 121
3. S. Kojima, N. Watanabe, M. Numata, T. Ogawa, and S. Matsuzaki Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background J. Gastroenterol. 38 2003 954 961
4. C.P. Day, and O.F. James Steatohepatitis: a tale of two "hits"? Gastroenterology 114 1998 842 845
5. J.C. Cohen, J.D. Horton, and H.H. Hobbs Human fatty liver disease: old questions and new insights Science 332 2011 1519 1523
6. T. Caballero, A. Gila, G. Sanchez-Salgado, P. Munoz de Rueda, J. Leon, S. Delgado, J.A. Munoz, M. Caba-Molina, A. Carazo, A. Ruiz-Extremera, and J. Salmeron Histological and immunohistochemical assessment of liver biopsies in morbidly obese patients Histol. Histopathol. 27 2012 459 466
7. F. Caballero, A. Fernandez, A.M. De Lacy, J.C. Fernandez-Checa, J. Caballeria, and C. Garcia-Ruiz Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH J. Hepatol. 50 2009 789 796
8. L. Hebbard, and J. George Animal models of nonalcoholic fatty liver disease Nat. Rev. Gastroenterol. Hepatol. 8 2011 35 44
9. M.J. Wolf, A. Adili, K. Piotrowitz, Z. Abdullah, Y. Boege, K. Stemmer, M. Ringelhan, N. Simonavicius, M. Egger, D. Wohlleber, A. Lorentzen, C. Einer, S. Schulz, T. Clavel, U. Protzer, C. Thiele, H. Zischka, H. Moch, M. Tschop, A.V. Tumanov, D. Haller, K. Unger, M. Karin, M. Kopf, P. Knolle, A. Weber, and M. Heikenwalder Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes Cancer Cell 26 2014 549 564
10. L. Miele, V. Valenza, G. La Torre, M. Montalto, G. Cammarota, R. Ricci, R. Masciana, A. Forgione, M.L. Gabrieli, G. Perotti, F.M. Vecchio, G. Rapaccini, G. Gasbarrini, C.P. Day, and A. Grieco Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease Hepatology 49 2009 1877 1887
11. P. Brun, I. Castagliuolo, V. Di Leo, A. Buda, M. Pinzani, G. Palu, and D. Martines Increased intestinal permeability in obese mice: New evidence in the pathogenesis of nonalcoholic steatohepatitis Am. J. Physiol. Gastrointest. Liver Physiol. 292 2007 G518 G525
12. V. Volynets, M.A. Kuper, S. Strahl, I.B. Maier, A. Spruss, S. Wagnerberger, A. Konigsrainer, S.C. Bischoff, and I. Bergheim Nutrition, intestinal permeability, and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease (NAFLD) Dig. Dis. Sci. 57 2012 1932 1941
13. K.C. El Kasmi, A.L. Anderson, M.W. Devereaux, S.A. Fillon, J.K. Harris, M.A. Lovell, M.J. Finegold, and R.J. Sokol Toll-like receptor 4-dependent Kupffer cell activation and liver injury in a novel mouse model of parenteral nutrition and intestinal injury Hepatology 55 2012 1518 1528
14. D.H. Dapito, A. Mencin, G.Y. Gwak, J.P. Pradere, M.K. Jang, I. Mederacke, J.M. Caviglia, H. Khiabanian, A. Adeyemi, R. Bataller, J.H. Lefkowitch, M. Bower, R. Friedman, R.B. Sartor, R. Rabadan, and R.F. Schwabe Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4 Cancer Cell 21 2012 504 516
15. E.J. Park, J.H. Lee, G.Y. Yu, G. He, S.R. Ali, R.G. Holzer, C.H. Osterreicher, H. Takahashi, and M. Karin Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression Cell 140 2010 197 208
16. S. Melgar, A. Karlsson, and E. Michaelsson Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: Correlation between symptoms and inflammation Am. J. Physiol. Gastrointest. Liver Physiol. 288 2005 G1328 G1338
17. P.A. Dawson, S. Huxley, B. Gardiner, T. Tran, J.L. McAuley, S. Grimmond, M.A. McGuckin, and D. Markovich Reduced mucin sulfonation and impaired intestinal barrier function in the hyposulfataemic NaS1 null mouse Gut 58 2009 910 919
18. K. Nagashima, T. Hisada, M. Sato, and J. Mochizuki Application of new primer-enzyme combinations to terminal restriction fragment length polymorphism profiling of bacterial populations in human feces Appl. Environ. Microbiol. 69 2003 1251 1262
19. T. Tanigawa, T. Watanabe, K. Otani, Y. Nadatani, F. Ohkawa, M. Sogawa, H. Yamagami, M. Shiba, K. Watanabe, K. Tominaga, Y. Fujiwara, K. Takeuchi, and T. Arakawa Rebamipide inhibits indomethacin-induced small intestinal injury: possible involvement of intestinal microbiota modulation by upregulation of alpha-defensin 5 Eur. J. Pharmacol. 704 2013 64 69
20. Y. Nakanishi, K. Murashima, H. Ohara, T. Suzuki, H. Hayashi, M. Sakamoto, T. Fukasawa, H. Kubota, A. Hosono, T. Kono, S. Kaminogawa, and Y. Benno Increase in terminal restriction fragments of Bacteroidetes-derived 16S rRNA genes after administration of short-chain fructooligosaccharides Appl. Environ. Microbiol. 72 2006 6271 6276
21. C. Bauer, P. Duewell, C. Mayer, H.A. Lehr, K.A. Fitzgerald, M. Dauer, J. Tschopp, S. Endres, E. Latz, and M. Schnurr Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome Gut 59 2010 1192 1199
22. S. De Minicis, L. Agostinelli, C. Rychlicki, G.P. Sorice, S. Saccomanno, C. Candelaresi, A. Giaccari, L. Trozzi, I. Pierantonelli, E. Mingarelli, M. Marzioni, G. Muscogiuri, M. Gaggini, A. Benedetti, A. Gastaldelli, M. Guido, and G. Svegliati-Baroni HCC development is associated to peripheral insulin resistance in a mouse model of NASH PLoS One 9 2014 e97136
23. B. Wang, S.H. Hsu, W. Frankel, K. Ghoshal, and S.T. Jacob Stat3-mediated activation of microRNA-23a suppresses gluconeogenesis in hepatocellular carcinoma by down-regulating glucose-6-phosphatase and peroxisome proliferator-activated receptor gamma, coactivator 1 alpha Hepatology 56 2012 186 197
24. V.M. de Lima, C.P. Oliveira, V.A. Alves, M.C. Chammas, E.P. Oliveira, J.T. Stefano, E.S. de Mello, G.G. Cerri, F.J. Carrilho, and S.H. Caldwell A rodent model of NASH with cirrhosis, oval cell proliferation and hepatocellular carcinoma J. Hepatol. 49 2008 1055 1061
25. H.L. Zhang, L.X. Yu, W. Yang, L. Tang, Y. Lin, H. Wu, B. Zhai, Y.X. Tan, L. Shan, Q. Liu, H.Y. Chen, R.Y. Dai, B.J. Qiu, Y.Q. He, C. Wang, L.Y. Zheng, Y.Q. Li, F.Q. Wu, Z. Li, H.X. Yan, and H.Y. Wang Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats J. Hepatol. 57 2012 803 812
26. J.G. Fox, Y. Feng, E.J. Theve, A.R. Raczynski, J.L. Fiala, A.L. Doernte, M. Williams, J.L. McFaline, J.M. Essigmann, D.B. Schauer, S.R. Tannenbaum, P.C. Dedon, S.A. Weinman, S.M. Lemon, R.C. Fry, and A.B. Rogers Gut microbes define liver cancer risk in mice exposed to chemical and viral transgenic hepatocarcinogens Gut 59 2010 88 97
27. S. Yoshimoto, T.M. Loo, K. Atarashi, H. Kanda, S. Sato, S. Oyadomari, Y. Iwakura, K. Oshima, H. Morita, M. Hattori, K. Honda, Y. Ishikawa, E. Hara, and N. Ohtani Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome Nature 499 2013 97 101
28. E. Gabele, K. Dostert, C. Hofmann, R. Wiest, J. Scholmerich, C. Hellerbrand, and F. Obermeier DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH J. Hepatol. 55 2011 1391 1399
29. M. Darnaud, J. Faivre, and N. Moniaux Targeting gut flora to prevent progression of hepatocellular carcinoma J. Hepatol. 58 2013 385 387
30. E. Seki, and B. Schnabl Role of innate immunity and the microbiota in liver fibrosis: Crosstalk between the liver and gut J. Physiol. 590 2012 447 458
31. T. Luedde, and R.F. Schwabe NF-kappaB in the liver-linking injury, fibrosis and hepatocellular carcinoma Nat. Rev. Gastroenterol. Hepatol. 8 2011 108 118
32. K. Miura, Y. Kodama, S. Inokuchi, B. Schnabl, T. Aoyama, H. Ohnishi, J.M. Olefsky, D.A. Brenner, and E. Seki Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice Gastroenterology 139 2010 323 334 e327